Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
Morgan Stanley Smith Barney LLC filed a Form 144 notice to sell 24,000 shares of Common stock. The filing lists multiple planned sales tied to restricted stock vesting under a registered plan on 03/18/2025, 02/13/2026, and 03/18/2026.
The filing shows vesting-related lot sizes of 7,205, 8,122, and 8,673 shares. A separate line lists 64,521,198 shares outstanding as of 07/09/2026 as a context figure.
ARVINAS, INC. director Laurie Smaldone Alsup reported equity awards consisting of restricted stock units and stock options. She was granted 15,527 RSUs, each representing a right to receive one share of common stock for no cash consideration upon settlement. Following this award, she directly holds 41,572 shares of common stock. She also received stock options covering 22,714 shares of common stock at an exercise price of $8.05 per share. Both the RSUs and the options vest in full on the earlier of June 24, 2027 or immediately before the first annual meeting of stockholders after the grant date, subject to her continued service with Arvinas.
ARVINAS, INC. director Leslie V. Norwalk reported routine equity compensation awards, not open-market trading. On June 24, 2026, Norwalk received 15,527 restricted stock units, each representing a right to one share of common stock for no cash payment, bringing direct common stock holdings to 41,572 shares.
Norwalk was also granted an option to buy 22,714 shares of common stock at an exercise price of $8.0500 per share, expiring on June 23, 2036. Both the RSUs and the option vest in full on June 24, 2027 or immediately before the first annual stockholder meeting after the grant date, if service with the company continues through vesting.
ARVINAS, INC. director Briggs Morrison reported equity awards consisting of restricted stock units and stock options. He received 15,527 shares of common stock as RSUs and 22,714 stock options with an exercise price of $8.05 per share. Following the grants, he directly holds 111,548 common shares and 22,714 options. The RSUs and options vest in full on the earlier of June 24, 2027 or immediately before the first annual stockholders’ meeting after the grant date, subject to his continued service with the company.
ARVINAS, INC. director Edward M. Kennedy Jr. reported new equity awards in the form of restricted stock units and stock options. He received 15,527 restricted stock units, each representing one share of common stock for no cash consideration upon settlement, and a stock option covering 22,714 shares at an exercise price of $8.05 per share.
Both the RSUs and the option were granted on June 24, 2026 and will vest in full on the earlier of June 24, 2027 or immediately before the first annual meeting of stockholders after the grant date, subject to his continued service with Arvinas. After these awards, he holds 54,957 shares of common stock directly and 29,333 shares indirectly through the Edward M. Kennedy Jr. 2011 Trusts For Children.
Arvinas, Inc. director Everett Cunningham reported equity awards made on June 24, 2026. He received 15,527 restricted stock units, each representing one share of common stock at no cost upon settlement, and a stock option for 22,714 shares at an exercise price of $8.05 per share, expiring on June 23, 2036. Both awards vest in full on the earlier of June 24, 2027 or immediately before the first annual stockholders’ meeting after the grant, subject to his continued service. Following these awards, Cunningham directly holds 41,572 shares of common stock.
Arvinas, Inc. granted equity awards to director Linda Bain. She received 15,527 restricted stock units, each representing one share of common stock for no cash consideration. Following the grant, she directly holds 41,572 common shares.
Bain was also granted stock options for 22,714 shares at an exercise price of $8.05 per share, expiring on June 23, 2036. Both the RSUs and options vest in full on the earlier of June 24, 2027 or immediately before the first annual meeting of stockholders after the grant date, subject to her continued service with Arvinas.
Arvinas, Inc. held its annual meeting of stockholders on June 24, 2026, where three proposals were put to a vote. Stockholders elected Class II directors Leslie V. Norwalk, Esq. and Randy Teel, Ph.D. to serve until the 2029 annual meeting of stockholders. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. In addition, stockholders ratified the appointment of Deloitte & Touche LLP as Arvinas’ independent registered public accounting firm for the fiscal year ending December 31, 2026.
ARVINAS, INC. Chief Financial Officer Andrew Saik reported an automatic sale of 5,696 shares of common stock at $8.159 per share. The sale was made by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on June 24, 2024, under a durable sale instruction, and was not a discretionary trade. After this transaction, he continues to hold 187,432 shares of common stock directly.
Arvinas, Inc. reports the proposed sale/settlement of 5,846 shares of Common Stock tied to the settlement of vested restricted stock units, scheduled to settle on 06/24/2026 through Morgan Stanley Smith Barney LLC. The excerpt also shows a prior disposition of 11,139 shares by Andrew Saik on 05/11/2026.